BMS-599626,an orally bioavailable pan-HER tyrosine kinase inhibitor with potential antineoplastic activity. BMS-599626 inhibits human epidermal growth factor receptors (HER) HER1, HER2 and HER4, thereby inhibiting the proliferation of tumor cells that overexpress these receptors.

1.HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Haluska P et al. Mol Cancer Ther. 2008 Sep;7(9):2589-98. Epub 2008 Sep

2. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Wong TW,et al. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6186-93.

3.Small molecules with EGFR-TK inhibitor activity. Albanell J,et al. Curr Drug Targets. 2005 May;6(3):259-74. Review.